NeoGenomics Wins Patent Infringement Lawsuit Against Natera, Clears Path for Broad Commercialization of RaDaR ST Assay.

NeoGenomics has been granted summary judgment in a patent infringement lawsuit against Natera, with the court ruling that Natera's asserted patent claims are invalid for claiming ineligible subject matter. The decision allows NeoGenomics to commercially develop the RaDaR ST assay, which has been launched to biopharma customers and submitted for clinical reimbursement coverage.

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions, has been granted summary judgment in a patent infringement lawsuit against Natera. The District Court for the Middle District of North Carolina ruled that Natera’s asserted patent claims are invalid for claiming ineligible subject matter [1][2][3]. This decision allows NeoGenomics to freely commercialize its RaDaR® ST assay, which has been launched to biopharma customers and submitted for clinical reimbursement coverage through the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services Program (MolDX) [1][2][3].

The court’s ruling means that NeoGenomics can continue to develop and market the RaDaR ST assay, which is designed to detect molecular residual disease (MRD) in cancer patients. This assay is part of NeoGenomics’ comprehensive menu of oncology-focused testing services, which serve a wide range of healthcare providers, including oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms [1][2][3].

“We are pleased with the Court’s decision to invalidate Natera’s asserted patents,” said Tony Zook, CEO of NeoGenomics. “NeoGenomics is committed to providing cancer patients with the most comprehensive array of diagnostic testing options to enable the highest quality of personalized care. This includes providing options for MRD testing, which is a critical component of modern cancer treatment” [1][2][3].

The decision underscores NeoGenomics’ commitment to innovation and intellectual property protection, which are essential for driving advancements in precision medicine. The company continues to vigorously defend its intellectual property rights to fuel the next wave of innovation and serve its patients [1][2][3].

References:
[1] https://www.marketscreener.com/news/court-rules-for-neogenomics-in-patent-infringement-lawsuit-against-natera-ce7c50ddd981f624
[2] https://www.businesswire.com/news/home/20250829527926/en/Court-Rules-for-NeoGenomics-in-Patent-Infringement-Lawsuit-Against-Natera
[3] https://www.stocktitan.net/news/NEO/court-rules-for-neo-genomics-in-patent-infringement-lawsuit-against-bldz897q37k9.html